Hepatic Neoplasms

Inclusion Criteria

- Present with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment.
 - There should not be more than five liver lesions on type visualized on CT.
 - The patient should be in a condition that allows subsequent treatment.
 - Be willing and able to continue study participation following administration of SH U 555 A to ensure completion of all procedures and observations required by the trial protocol.
 - Sign and date fully informed consent prior to entry into the study.

Exclusion Criteria

- Patients under 18 years of age.
 - Patients weighing less than 35 kg.
 - Patients who have received any investigational drug within the 30 days prior to entering this study.
 - Patients who have previously entered this study or any other study performed with SH U 555 A.
 - Women who are pregnant or who are of childbearing potential and have not had a negative urine pregnancy test immediately prior to the administration of SH U 555 A.  The urine pregnancy test should be performed in accordance with the manufacturer's recommendations.
 - Lactating women.
 - Patients who have any contraindication to MRI examination.
 - Patients who have received any contrast material in the 24 hours prior to SH U 555 A injection, or who are scheduled to receive any contrast material within 24 hours afterwards. (In the case of any liver specific agent (e.g. MnDPDP, SPIOs, Gd-BOPTA) this will be extended to 14 days prior to the study).
 - Patients who have received Lipiodol contrast material at any time in the past or are scheduled to receive this during the study period.
 - Patients who are clinically unstable and whose clinical course during the observation period is unpredictable (e.g. due to previous surgery).
 - Patients scheduled for liver biopsy within 24 hours, or who had a biopsy within the 24 hours prior to planned SH U 555 A injection.
 - Patients who are scheduled for, or are likely to require, surgery within 24 hours after SH U 555 A injection.
 - Patients with a history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents.
 - Patients with known hypersensitivity to any of the ingredients of SH U 555 A.
 - Patients with already clear op-indication